We are partnering with third parties to prepare sustained release formulations and/or deliver therapeutic agents, including small and large molecules and gene and cell therapies, to treat retinal diseases.
Our drug administration technology enables routine administration to deliver drugs to specific back-of-eye tissues, including the suprachoroidal, sub-retinal and other small spaces.
Our drug formulations are designed to suit the unique ocular environments into which they are delivered, resulting in better drug movement and therapeutic benefits, and provide clinical effects lasting up to twelve months in duration from a single administration.
If you would like to discuss a potential partnership with Oxular, working with either our device or drug formulation technologies, please contact us on the form below.